TrialEuropean journal of clinical pharmacology2021

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.

Markus Zeitlinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.